Takeda drug candidates go to new firm

Abstract

Takeda Pharmaceutical will inject eight drug candidates into a new biotech venture, Scohia Pharma. Innovation Network Corp. of Japan, a venture capital fund partly financed by the Japanese government, will own about 70% of the venture; the rest will be held by Takeda and its subsidiary Medipal Holdings. The drug candidates are in the renal, metabolic, and cardiovascular areas. The partners expect the spin-off to conduct research more efficiently while benefiting from Takeda scientists’ input.